Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $40M Series A financing round. The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422384739/en/
Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI
The funding will be used to advance the company’s lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis, which will be entering Phase 1 studies. Rubedo is also developing additional therapies that selectively target senescent cells in pulmonary diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF), with a program recipient of a substantial CIRM grant last year.
“We’re delighted to attract this top-tier syndicate co-led by Khosla Ventures and Ahren Innovation Capital. This significant influx of financing will allow us to advance our first clinical candidate into human studies,” said Marco Quarta, CEO & Co-Founder of Rubedo Life Sciences.
“As people live longer, improving quality of life is paramount,” said Alex Morgan, Partner, Khosla Ventures. “Rubedo is targeting senescent, or aging, cells that drive age-related diseases. This first trial can bring us another step closer to achieving better healthspan.”
“Our mission is to invest in transformational companies that will change the world for the better, serving vast markets,” said Alice Newcombe Ellis, Founding & General Partner, Ahren Innovation Capital. “We believe that Rubedo’s transformative approach to targeting senescent cells is an impressive step towards the development of chronic age-related therapies, which will advance biotech from treatment to prevention or disease reversal.”
“The significant experience and capital that our investors bring to Rubedo will help the company rapidly advance our programs,” said Ali Siam, Chief Business Officer, Rubedo Life Sciences. “We look forward to working with these leaders, whose vast experience in clinical development will be invaluable as we enter the next phase of growth at Rubedo.”
Rubedo’s Alembic™ drug discovery platform enables the identification of specific druggable targets for development into therapeutics that selectively target pathologic cells, such as various types of senescent cells, that drive the process of biological aging. Senescence is the process by which a cell ages and permanently stops dividing but does not die. Any cell can potentially become senescent. Over time, large numbers of senescent cells can build up in tissues throughout the body and release pathologic factors. When they reach a critical mass, they cause chronic inflammation and damage leading to fibrosis and tissue degeneration which drive many age-related diseases.
About Rubedo Life Sciences
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target various types of senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, visit www.rubedolife.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422384739/en/
Contact information
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mesmerise to collaborate with Mayo Clinic to Transform Medical Education and Healthcare Workforce Training13.1.2025 23:10:00 CET | Press Release
Mesmerise is proud to announce the creation of NeuRealities, Inc., a transformative company designed to revolutionize medical education and healthcare training. As part of a know-how agreement with Mayo Clinic, the new company seeks to leverage Mayo Clinic’s unparalleled clinical expertise and trusted knowledge with Mesmerise’s pioneering advancements in AI-powered spatial computing to set a new standard for excellence in immersive learning experiences. NeuRealities aims to introduce an open-standards digital platform that redefines how healthcare professionals learn and train. By integrating hyper-realistic AI-enabled digital humans, adaptive immersive experiences, and dynamic content tailored to individual learners, the platform can address critical gaps in medical education. Its first initiative—CT training for radiologic technicians—delivers interactive, hands-on scenarios that simplify complex medical concepts, allowing the potential for training to be more efficient, accessible,
Jefferies to Hold Global Trading Day on January 16 to Support Los Angeles Wildfire Relief Efforts13.1.2025 22:15:00 CET | Press Release
Jefferies announced today that it will hold a Global Trading Day on January 16, 2025, to raise funds for organizations supporting first responders and those impacted by the fires. Jefferies will donate 100% of net global commissions on January 16 for all trading in equities and fixed income by the Firm’s clients. Jefferies will also make a $1 million donation and encourage its nearly 6,000 employees to personally support relief efforts. During the month following this Global Trading Day, contributions will be carefully allocated to qualified charities to ensure the proceeds go directly to support the people and communities most in need. Rich Handler, CEO, and Brian Friedman, President of Jefferies, said: “We are heartbroken by the wildfires causing unfathomable destruction in the Los Angeles area. Our firm was founded in Los Angeles 62 years ago, and it has always been a resilient community, full of dynamism, opportunity and strength. Our hearts go out to all those affected, and we sta
Global Relay placed in 2025 Gartner® Magic Quadrant for Digital Communications Governance and Archiving Solutions13.1.2025 17:00:00 CET | Press Release
Global Relay, a leading and innovative provider of solutions in digital communications compliance and recordkeeping, today announced that Global Relay has been positioned by Gartner as a Leader in the Magic Quadrant for Digital Communications Governance and Archiving Solutions for its offerings, Global Relay Archive, Global Relay App, and Global Relay Connectors. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. “Global Relay has been delivering compliance solutions to regulated industries for 25 years and we continue to invest more than ever in technology, infrastructure, and people for continued growth,” says Warren Roy, founder and CEO of Global Relay. “Our recent announcements around new AI, voice, and surveillance offerings ─ along with flagship office openings ─ are testament to this commitment.” Magic Quadrant reports are a culmination of rigorous, fact-based research in specific markets, providing a
AEM Launches WMO-Compliant Automated Weather Station to Elevate Global Weather Monitoring13.1.2025 16:00:00 CET | Press Release
AEM, the essential source for environmental insights, today announced its WMO-compliant AEM Apex Automated Weather Station (AWS). This state-of-the-art solution sets a new benchmark for precision, reliability, and durability, meeting the strict standards of the World Meteorological Organization (WMO). Designed to address the toughest challenges in weather monitoring, the WMO-compliant AWS offers unparalleled accuracy and performance for a variety of critical applications, from localized climate research to large-scale weather networks. Key Benefits of the WMO-Compliant AWS Precision Data for Better Decisions: Provides WMO-compliant measurements with strict tolerances to support critical applications. Seamless Global Collaboration: Enables efficient data sharing with regional and global partners, fostering enhanced coordination for monitoring and forecasting. Reliability in Extreme Conditions: Built to deliver continuous, accurate data with minimal maintenance, even in the most demandin
Starr Names Peter Hirs to Succeed Howard Smith as CFO13.1.2025 15:30:00 CET | Press Release
Starr announced that Peter Hirs has been named the company’s chief financial officer, effective January 13, succeeding Howard I. Smith, who is retiring after more than 40 years at Starr and related entities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113071409/en/ Peter Hirs, chief financial officer, Starr (Photo: Business Wire) Hirs brings significant finance and insurance experience to Starr, having spent the past 20 years at a global insurance carrier, where he managed regional finance teams across the world and led mergers and acquisitions activities. In his new role, Hirs will oversee the organization’s global finance operations. He is based at Starr’s head office in New York. Smith had led Starr’s financial operations since 2005, when Maurice R. “Hank” Greenberg, Starr’s chairman emeritus, re-established Starr as a free-standing investment and insurance organization, and he worked closely with Hank prior to that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom